ATE236975T1 - Haarnadelförmiges ribozym - Google Patents

Haarnadelförmiges ribozym

Info

Publication number
ATE236975T1
ATE236975T1 AT93914943T AT93914943T ATE236975T1 AT E236975 T1 ATE236975 T1 AT E236975T1 AT 93914943 T AT93914943 T AT 93914943T AT 93914943 T AT93914943 T AT 93914943T AT E236975 T1 ATE236975 T1 AT E236975T1
Authority
AT
Austria
Prior art keywords
polyribonucleotide
ribozyme
hairpin
shaped
forth
Prior art date
Application number
AT93914943T
Other languages
English (en)
Inventor
Eiko Otsuka
Makoto Koizumi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE236975T1 publication Critical patent/ATE236975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93914943T 1992-07-02 1993-07-02 Haarnadelförmiges ribozym ATE236975T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17570692 1992-07-02
JP23691692 1992-09-04
PCT/JP1993/000907 WO1994001549A1 (en) 1992-07-02 1993-07-02 Looped, hairpin ribozyme

Publications (1)

Publication Number Publication Date
ATE236975T1 true ATE236975T1 (de) 2003-04-15

Family

ID=26496887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93914943T ATE236975T1 (de) 1992-07-02 1993-07-02 Haarnadelförmiges ribozym

Country Status (8)

Country Link
US (1) US5631115A (de)
EP (1) EP0653488B1 (de)
AT (1) ATE236975T1 (de)
AU (1) AU672018B2 (de)
CA (1) CA2139411A1 (de)
DE (1) DE69332856D1 (de)
NO (1) NO311258B1 (de)
WO (1) WO1994001549A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19532651A1 (de) * 1995-09-05 1997-03-06 Aloysius Dr Dickgreber Mittel zur therapeutischen Anwendung bei HIV-Infektionen
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US6274369B1 (en) * 1996-02-02 2001-08-14 Invitrogen Corporation Method capable of increasing competency of bacterial cell transformation
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (de) 2000-10-12 2003-07-16 University of Rochester Zusammensetzungen die die proliferation von krebszellen hemmen
JP2005532263A (ja) 2002-02-06 2005-10-27 ヴァイコー テクノロジーズ， インコーポレイテッド 抗梗塞分子
EP1534729A2 (de) * 2002-02-26 2005-06-01 University of Utah Research Foundation Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
AU2003298921A1 (en) * 2002-12-04 2004-06-23 Algos Therapeutics, Inc. Methods and materials for modulating trpm2
JP5562521B2 (ja) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
WO2007044607A2 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8093369B2 (en) * 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
AU2006304321B2 (en) 2005-10-14 2012-10-04 Musc Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
CA2981308C (en) 2006-09-21 2020-12-22 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
US9279127B2 (en) * 2006-11-01 2016-03-08 The Medical Research Fund At The Tel-Aviv Sourasky Medical Center Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
EP2682400B1 (de) 2007-08-28 2017-09-20 Uab Research Foundation Synthetische Apolipoprotein E nachahmende Polypeptide und Anwendungsverfahren
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2268664B1 (de) * 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Doc1-zusammensetzungen und verfahren zur behandlung von krebs
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
EP2853897A1 (de) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensorische Rezeptoren für chronische Müdigkeit und Schmerzen und Verwendungen davon
EP2370080A1 (de) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 als zieltherapeutikum bei herzkrankheiten
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2986317A4 (de) 2013-04-15 2016-10-05 Yeda Res & Dev Hemmung von rip-kinasen zur behandlung lysosomaler speicherkrankheiten
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
US11123435B2 (en) 2016-08-03 2021-09-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115999T1 (de) * 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
CA1340323C (en) * 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences

Also Published As

Publication number Publication date
DE69332856D1 (de) 2003-05-15
AU4513093A (en) 1994-01-31
EP0653488B1 (de) 2003-04-09
AU672018B2 (en) 1996-09-19
NO311258B1 (no) 2001-11-05
EP0653488A4 (de) 1997-01-15
NO945103L (no) 1995-03-02
NO945103D0 (no) 1994-12-30
CA2139411A1 (en) 1994-01-20
US5631115A (en) 1997-05-20
EP0653488A1 (de) 1995-05-17
WO1994001549A1 (en) 1994-01-20

Similar Documents

Publication Publication Date Title
ATE236975T1 (de) Haarnadelförmiges ribozym
DE69823481D1 (de) Wegwerfbare, vorgefüllte medikamentenkartusche
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
ES2130428T3 (es) Cristales de insulina asp-b28.
DK1295600T3 (da) Lægemiddel baseret på gestagener til dermal anvendelse indeholdende ascorbinsyre og/eller salte deraf
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
TR200003113T2 (tr) 3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması.
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CY1106235T1 (el) Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων
ATE291586T1 (de) Humanes antibiotisches protein
IT1317930B1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
ATE28188T1 (de) Antikonvulsive mittel.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
DE3879985D1 (de) Anticonvulsive agenzien.
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
ES2053834T3 (es) Un metodo para la preparacion de una sustancia terapeutica.
ES2185147T3 (es) Nuevos usos medicos del orosomucoide.
ES1032126Y (es) Juego esterilizable para la autoinyeccion de drogas.
IT1298394B1 (it) Siringa ipodermica monouso.
FR2764506B1 (fr) Composition therapeutique ou hygienique a liberation controlee et prolongee de principe(s) actif(s), notamment a usage ophtalmique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties